FDA Approves Symtuza For Treatment Of HIV-1 Infection
The U.S. Food and Drug Administration (FDA) has approved Janssen’s Symtuza, the first and only complete, darunavir-based single-tablet regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) in treatment-naïve and certain virologically suppressed adults. Symtuza combines the proven high barrier to resistance of darunavir with a formulation designed for improved tolerability and the convenience of…
Xarelto Reduces Cost, Hospital Stays For Some Pulmonary Embolism Patients
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the MERCURY PE study, which showed that people with low-risk pulmonary embolism (PE) treated with Xarelto (rivaroxaban) and discharged from the emergency department had significantly reduced time in the hospital and a median savings of $2,496 in per patient costs, compared to standard of care in-patient treatment.…
Study: Fewer Strokes With Xarelto Versus Warfarin In Frail Patients
The Janssen Pharmaceutical Companies of Johnson & Johnson on Thursday announced new real-world data that showed frail patients with non-valvular atrial fibrillation (NVAF) experienced significantly fewer strokes and systemic emboli when treated with Xarelto (rivaroxaban) over a two-year period compared to those taking warfarin. Specifically, long-term Xarelto use reduced the risk of stroke and systemic embolism by 32…
Once-Daily, Single-Pill For The Treatment Of HIV-1 Approved In Europe
The European Commission has granted marketing authorization to the Janssen Pharmaceutical Companies of Johnson & Johnson for Juluca (dolutegravir 50mg [ViiV Healthcare]/rilpivirine 25mg [Janssen Sciences Ireland UC]).1 ViiV Healthcare, as the marketing authorization holder, will market dolutegravir/rilpivirine in all countries in the European Union and European Economic Area. Dolutegravir/rilpivirine is the first two-drug regimen, once-daily, single-pill for the…
Janssen’s Invokana Reduces Heart Failure In Type 2 Diabetes Patients
The Janssen Pharmaceutical Companies of Johnson & Johnson provided results of a new analysis showing that Invokana (canagliflozin) significantly reduced the risk of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) at high CV risk. This exploratory analysis from the CANVAS Program was featured as a late-breaking oral…
New Analyses From Darunavir-Based STR Pivotal Phase 3 Trials
The Janssen Pharmaceutical Companies of Johnson & Johnson announced post-hoc analyses from the pivotal Emerald and Amber Phase 3 trials of its investigational, complete, once-daily, single-tablet regimen (STR) of darunavir 800mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg (D/C/F/TAF) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The analyses were presented at the annual…
